Kadono Shojiro, Sakamoto Akihisa, Kikuchi Yasufumi, Oh-Eda Masayoshi, Yabuta Naohiro, Yoshihashi Kazutaka, Kitazawa Takehisa, Suzuki Tsukasa, Koga Takaki, Hattori Kunihiro, Shiraishi Takuya, Haramura Masayuki, Kodama Hirofumi, Ono Yoshiyuki, Esaki Toru, Sato Haruhiko, Watanabe Yoshiaki, Itoh Susumu, Ohta Masateru, Kozono Toshiro
Fuji Gotemba Research Labs, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Biochem Biophys Res Commun. 2005 Jan 28;326(4):859-65. doi: 10.1016/j.bbrc.2004.11.108.
Selective factor VIIa-tissue factor complex (FVIIa/TF) inhibition is seen as a promising target for developing new anticoagulant drugs. A novel peptide mimetic factor VIIa inhibitor, ethylsulfonamide-d-biphenylalanine-Gln-p-aminobenzamidine, shows 100-fold selectivity against thrombin in spite of its large P3 moiety, unlike previously reported FVIIa/TF selective inhibitors. X-ray crystal structure analysis reveals that the large P3 moiety, d-biphenylalanine, and the small P4 moiety, ethylsulfonamide, make novel interactions with the 170-loop and Lys192 of FVIIa/TF, respectively, accompanying ligand-induced conformational changes of the 170-loop, Gln217, and Lys192. Structural comparisons of FVIIa with thrombin and amino acid sequence comparisons among coagulation serine proteases suggest that these interactions play an important role in achieving selective inhibition for FVIIa/TF.
选择性抑制因子VIIa-组织因子复合物(FVIIa/TF)被视为开发新型抗凝药物的一个有前景的靶点。一种新型的肽模拟因子VIIa抑制剂,乙基磺酰胺-d-联苯丙氨酸-Gln-对氨基苯甲脒,尽管其P3部分较大,但与先前报道的FVIIa/TF选择性抑制剂不同,它对凝血酶具有100倍的选择性。X射线晶体结构分析表明,大的P3部分d-联苯丙氨酸和小的P4部分乙基磺酰胺分别与FVIIa/TF的170环和Lys192形成新的相互作用,同时伴随着配体诱导的170环、Gln217和Lys192的构象变化。FVIIa与凝血酶的结构比较以及凝血丝氨酸蛋白酶之间的氨基酸序列比较表明,这些相互作用在实现对FVIIa/TF的选择性抑制中起重要作用。